Rethinking Antisense Oligonucleotide Therapies for ALS
Author Information
Author(s): D. Ito, K. Okada
Primary Institution: Keio University School of Medicine
Hypothesis
Can antisense oligonucleotides effectively treat amyotrophic lateral sclerosis (ALS)?
Conclusion
Antisense oligonucleotides have shown proof of mechanism by reducing target proteins but have not consistently demonstrated clinical benefits in ALS patients.
Supporting Evidence
- Tofersen reduced SOD1 protein levels in cerebrospinal fluid but did not improve clinical outcomes.
- Clinical trials for other antisense oligonucleotides targeting different genes have also shown no significant clinical benefits.
- Real-world evidence suggests a reduction in neurofilament light chain levels with tofersen treatment.
Takeaway
Scientists are trying to use special drugs called antisense oligonucleotides to help people with ALS, but so far, they haven't made people feel better even though they can lower some harmful proteins.
Methodology
This review discusses various clinical trials and outcomes of antisense oligonucleotide therapies for ALS.
Potential Biases
Potential biases may arise from the limited number of participants and the nature of the trials conducted.
Limitations
The clinical benefits of antisense oligonucleotides in ALS have not been definitively proven despite reductions in target proteins.
Participant Demographics
Participants included individuals with SOD1 mutations and other genetic backgrounds related to ALS.
Statistical Information
P-Value
0.97
Confidence Interval
95% CI, 0.4–6.7
Statistical Significance
p=0.97
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website